読み込み中
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
前日終値
$2.48
+$0.11 · +4.64%
日中の時刻はETです。市場データは遅延する場合があります。
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
日中レンジ
現在 $2.48
52週レンジ
現在 $2.48
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
32
割高
センチメント
50
まちまち
リスク
66
高リスク
モメンタム
28
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
日中レンジ
現在 $2.48
52週レンジ
現在 $2.48
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 119.9万 USD | 239.2万 USD | 70.9万 USD | 122.2万 USD | 130.6万 USD |
| 売上原価 | 39.6万 USD | 50.8万 USD | 48.8万 USD | 72.5万 USD | 71.6万 USD |
| 粗利益 | 80.3万 USD | 188.4万 USD | 22.1万 USD | 49.7万 USD | 59万 USD |
| 研究開発 | 1204.1万 USD | 813.7万 USD | 906.6万 USD | 937万 USD | 709.2万 USD |
| 販売・一般管理 | 1204.9万 USD | 1026.9万 USD | 1218.4万 USD | 917万 USD | 1095.4万 USD |
| 営業費用 | 2409万 USD | 1840.6万 USD | 2125万 USD | 1854万 USD | 1804.6万 USD |
| 支払利息 | — | — | — | — | 4000 USD |
| 減価償却費と償却費 | 122.6万 USD | 95.8万 USD | 94.6万 USD | 89.3万 USD | 91.4万 USD |
| 営業利益 | −2328.7万 USD | −1652.2万 USD | −2102.9万 USD | −1804.3万 USD | −1745.6万 USD |
| 純利益 | −2270.4万 USD | −1597.3万 USD | −2141.3万 USD | −1883.5万 USD | −1704.5万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$10.00
上昇余地（303.23%）評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
